• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:03:59 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email
    SC 13G/A 1 tm216476d42_sc13ga.htm SC 13G/A

     

    CUSIP No: 71880W303

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Phio Pharmaceuticals Corp.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    71880W303
    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 71880W303

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
         
    BENEFICIALLY
    (6) SHARED VOTING POWER **
    OWNED BY
      228,896
    EACH
     
    REPORTING (7) SOLE DISPOSITIVE POWER
     
    PERSON WITH 0
         
     
    (8) SHARED DISPOSITIVE POWER **
     
      228,896
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      228,896
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      4.0%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 71880W303

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
         
    BENEFICIALLY
    (6) SHARED VOTING POWER **
    OWNED BY
      228,896
    EACH
     
    REPORTING (7) SOLE DISPOSITIVE POWER
     
    PERSON WITH 0
         
     
    (8) SHARED DISPOSITIVE POWER **
     
      228,896
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      228,896
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      4.0%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 71880W303

     

    Item 1.

     

    (a)Name of Issuer

     

    Phio Pharmaceuticals Corp. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    257 Simarano Drive, Suite 101, Marlborough, Massachusetts 01752

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e) CUSIP Number

     

    71880W303

     

     

     

    CUSIP No: 71880W303

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 5,780,592 Shares outstanding as of November 6, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     

     

    CUSIP No: 71880W303

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No: 71880W303

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.     HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which was   Name: Brian Sopinsky
    previously filed   Title: Secretary

     

    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    

       

     

     

    CUSIP No: 71880W303

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         
         

    *Previously filed

     

     

    Get the next $PHIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

    King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest dose concentration of PH-762. Pathology results for these patients are expected in Q1 2026. PH-762 is a potent silencer of the PD-1 gene implicated in various forms of skin cancer.The Phase 1b clinic

    11/25/25 11:30:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

    Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention Center from November 18-19, 2025.Podium Presentation Details are as follows: Title: INTASYL® Synthesized siRNA Drug TechnologyDown-regulating Gene Expression Presenting Author:  Melissa Maxwell,

    11/17/25 8:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third PatientSafety Monitoring Committee Issues Favorable Review of Safety Data at Maximum Dose of INTASYL PH-762Warrant Inducement Financing in November 2025 for Expected Net Proceeds Totaling Approximately $12.1 million, Extending Cash Runway into the First Half of 2027King of Prussia, Pennsylvania--(Newsfile Corp. - November 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a c

    11/13/25 4:15:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    SEC Filings

    View All

    SEC Form 424B3 filed by Phio Pharmaceuticals Corp.

    424B3 - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    12/4/25 4:02:41 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Phio Pharmaceuticals Corp.

    EFFECT - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    12/4/25 12:15:26 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    11/25/25 4:12:46 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $6,350 worth of shares (5,000 units at $1.27), increasing direct ownership by 2% to 276,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/19/25 12:47:40 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Ferrara Robert L was granted 23,100 shares, increasing direct ownership by 147% to 38,766 units (SEC Form 4)

    4/A - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    9/15/25 4:02:03 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

    6/14/21 6:22:20 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $6,350 worth of shares (5,000 units at $1.27), increasing direct ownership by 2% to 276,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/19/25 12:47:40 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 5:00:01 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o

    10/21/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in t

    9/23/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    11/13/24 11:20:45 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    2/6/24 10:30:10 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    2/8/23 6:07:04 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care